Kaposi sarcoma (KS) remains a challenge. Its classic or Mediterranean form tends to be benign. In transplant recipients it may be less so. As part of the AIDS pandemic, of which it was an original defining component, it may be life-threatening. It is due to human herpesvirus-8, which is necessary but not sufficient to produce the disease. KS has a low prevalence in the general population of the United States and United Kingdom, with an intermediate rate in Italy and Greece, and a high one in parts of Africa. In Italy, hot spots include its southern regions, the Po River Valley, and Sardinia, possibly related to a high density of blood-sucking insects. An important challenge is to treat KS patients without immunocompromising them. The potential of effective anti-herpes virus therapy and the use of sirolimus in transplantation recipients have added new opportunities for KS prevention.
|Titolo:||Kaposi’s sarcoma: a continuing conundrum|
|Data di pubblicazione:||2008|
|Citazione:||Kaposi’s sarcoma: a continuing conundrum / SCHWARTZ RA; MICALI G; NASCA MR; SCUDERI L. - In: JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY. - ISSN 0190-9622. - 59 (2)(2008), pp. 179-206.|
|Appare nelle tipologie:||1.1 Articolo in rivista|